

Sub D1
C1
1. (Twice Amended) A method of inducing a cytotoxic immune response against a target cell in a mammal, the method comprising:

administering to a mammal a combination of (i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen expressed on a target cell and interleukin 2, and (ii) an angiogenesis inhibitor having binding affinity for $\alpha_v\beta_3$ integrin, wherein the combination induces a cytotoxic immune response against the target cell that is greater than a response induced by the immunoconjugate alone.

C2
4. (Amended) The method of claim 1, wherein the angiogenesis inhibitor having binding affinity for $\alpha_v\beta_3$ integrin is co-administered together with the immunoconjugate.

5. (Amended) The method of claim 1, wherein the angiogenesis inhibitor having binding affinity for $\alpha_v\beta_3$ integrin is administered prior to the immunoconjugate.

Sub D2
C3
8. (Twice Amended) The method of claim 1, wherein the immunoconjugate is a fusion protein comprising, in an amino-terminal to carboxy-terminal direction, (i) the antibody binding site comprising an immunoglobulin variable region capable of binding a target antigen expressed on a target cell, an immunoglobulin CH1 domain, an immunoglobulin CH2 domain, and (ii) interleukin 2.

C4
9. (Amended) The method of claim 8, wherein the antibody binding site further comprises a CH3 domain interposed between the CH2 domain and interleukin-2.

12. (Twice Amended) A method of inducing a cytotoxic immune response against a cancer cell in a mammal, the method comprising:

C5
administering to a mammal a combination of (i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen expressed on a cancer cell and interleukin-2, and (ii) an angiogenesis inhibitor having binding affinity for $\alpha_v\beta_3$ integrin, wherein the combination induces a cytotoxic immune response against the cancer cell that is greater than a response induced by the immunoconjugate alone.

13. (Amended) The method of claim 12, wherein the angiogenesis inhibitor having binding affinity for $\alpha_v\beta_3$ integrin is co-administered together with the immunoconjugate.

C6

14. (Amended) The method of claim 12, wherein the angiogenesis inhibitor having binding affinity for $\alpha_v\beta_3$ integrin is administered prior to the immunoconjugate.

17. (Twice Amended) The method of claim 12, wherein the immunoconjugate is a fusion protein comprising, in an amino-terminal to carboxy-terminal direction, (i) the antibody binding site comprising an immunoglobulin variable region capable of binding a target antigen expressed on a target cell, an immunoglobulin CH1 domain, an immunoglobulin CH2 domain, and (ii) interleukin-2.

C7

18. (Amended) The method of claim 17, wherein the antibody binding site further comprises a CH3 domain interposed between the CH2 domain and interleukin-2.

C8

20. (Twice Amended) A composition for inducing an immune response against a target cell in a mammal, the composition comprising in combination:

(i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen expressed on a target cell and interleukin-2, and (ii) an angiogenesis inhibitor having binding affinity for $\alpha_v\beta_3$ integrin,

wherein the combination induces a cytotoxic immune response against the target cell that is greater than a response induced by the immunoconjugate alone.

23. (Twice Amended) The composition of claim 20, wherein the immunoconjugate is a fusion protein comprising, in an amino-terminal to carboxy-terminal direction, (i) the antibody binding site comprising an immunoglobulin variable region capable of binding a target antigen expressed on a target cell, an immunoglobulin CH1 domain, an immunoglobulin CH2 domain, and (ii) interleukin-2.

24. (Amended) The composition of claim 23, wherein the antibody binding site further comprises a CH3 domain between the CH2 domain and interleukin-2.

C11

31. (Twice Amended) A method for reducing the size of a tumor in a mammal, the method comprising:

C11 administering to a mammal (i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen expressed on a target cell in a tumor and interleukin-2, and (ii) an angiogenesis inhibitor having binding affinity for $\alpha_v\beta_3$ integrin,

wherein the combination induces a reduction in size of the tumor that is greater than a reduction in size induced by the immunoconjugate alone.

C12 32. (Amended) The method of claim 31, wherein the angiogenesis inhibitor having binding affinity for $\alpha_v\beta_3$ integrin is co-administered together with the immunoconjugate.

33. (Amended) The method of claim 31, wherein the angiogenesis inhibitor having binding affinity for $\alpha_v\beta_3$ integrin is administered prior to the immunoconjugate.

Sub D5
C13 36. (Twice Amended) The method of claim 31, wherein the immunoconjugate is a fusion protein comprising, in an amino-terminal to carboxy-terminal direction, (i) the antibody binding site comprising an immunoglobulin variable region capable of binding a target antigen expressed on a target cell, an immunoglobulin CH2 domain, and (ii) interleukin-2.